The Acetylcysteine for Contrast-Induced Nephropathy Trial
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of acetylcysteine compared to placebo
for the contrast-induced nephropathy prevention, between 48 and 96 hours after procedures
that use contrast.
Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the
procedure.